Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality

Goodkin, Karl; Wilkie, Frances L.; Concha, Mauricio; Hinkin, Charles H.; Symes, Stephen; Baldewicz, Teri; Asthana, Deshratn; Fujimura, Robert K.; Lee, D.; Zuilen, Maria H. van; Khamis, Imad; Shapshak, Paul; Eisdorfer, Carl

doi:10.1016/s0895-4356(01)00445-0

Cited by 110 publications

(77 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Individuals over 50 years of age make up approximately 11% of the AIDS population in the United States and this population is expected to grow with improved longevity of patients on HAART (40). Prolonged survival of AIDS patients can result in multiple exposures to HIV of different strains that may carry resistance mutations.…”

Section: Aging Hiv and Haartmentioning

confidence: 99%

Changing Patterns in the Neuropathogenesis of HIV During the HAART Era

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Aging Hiv and Haartmentioning

confidence: 99%

Changing Patterns in the Neuropathogenesis of HIV During the HAART Era

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Human immunodeficiency virus (HIV) infection in older patients (age > 50 years) is becoming increasingly common in developed countries as HIV seropositive individuals live longer because of potent antiretroviral treatment (1). Simultaneously, the development and expression of aging related brain changes among HIV-infected patients is evolving.…”

Section: Introductionmentioning

confidence: 99%

Cortical Atrophy and White Matter Hyperintensities in HIV: The Hawaii Aging with HIV Cohort Study

McMurtray

Nakamoto

Shikuma

et al. 2008

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

show abstract

“…HIV-associated dementia [HAD; 9,20,7], represents the most severe form of AIDS-related neuropsychiatric impairment [23] and the average survival after symptom onset is 6 months [21]. In the early phases of HIV infection, virus invades the central nervous system (CNS) tissues from peripheral cell populations sustained particularly by infected T cells and monocytes/macrophages.…”

Section: Introductionmentioning

confidence: 99%

EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-γ: Role of JAK/STAT1 signaling and implications for HIV-associated dementia

et al. 2006

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-1 infection of the central nervous system occurs in the vast majority of HIV infected patients. HIV-associated dementia (HAD) represents the most severe form of HIV-related neuropsychiatric impairment and is associated with neuropathology involving HIV proteins and activation of proinflammatory cytokine circuits. Interferon-γ (IFN-γ) activates the JAK/STAT1 pathway, a key regulator of inflammatory and apoptotic signaling, and is elevated in brains of HIV-1 infected brains progressing to HAD. Recent reports suggest that green tea derived (-)-epigallocatechin-3-gallate (EGCG) can attenuate neuronal damage mediated by this pathway in conditions such as brain ischemia. In order to investigate the therapeutic potential of EGCG to mitigate the neuronal damage characteristic of HAD, IFN-γ was evaluated for its ability to enhance well-known neurotoxic properties of HIV-1 proteins gp120 and Tat in primary neurons and mice. Indeed, IFN-γ enhanced the neurotoxicity of gp120 and Tat via increased JAK/STAT signaling. Additionally, primary neurons pretreated with a JAK1 inhibitor or those derived from STAT1-deficient mice were largely resistant to the IFN-γ enhanced neurotoxicity of gp120 and Tat. Moreover, EGCG treatment of primary neurons from normal mice reduced IFN-γ enhanced neurotoxicity of gp120 and Tat, while attenuating JAK/STAT1 pathway activation. EGCG was also found to attenuate the neurotoxic properties of HIV-1 proteins in the presence of IFN-γ in vivo. Taken together, these data suggest that EGCG attenuates the neurotoxicity of IFN-γ augmented neuronal damage from HIV-1 gp120 and Tat both in vitro and in vivo. Thus EGCG ‡

show abstract

Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality

Cited by 110 publications

References 65 publications

Changing Patterns in the Neuropathogenesis of HIV During the HAART Era

Changing Patterns in the Neuropathogenesis of HIV During the HAART Era

Cortical Atrophy and White Matter Hyperintensities in HIV: The Hawaii Aging with HIV Cohort Study

EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-γ: Role of JAK/STAT1 signaling and implications for HIV-associated dementia

Contact Info

Product

Resources

About